Digestive Diseases and Sciences

, Volume 39, Issue 2, pp 393–401

Recombinant human epidermal growth factor prevents sclerotherapy-induced esophageal ulcer and stricture formations in pigs

  • Claus Orloff Juhl
  • Lone Susanne Jensen
  • Torben Steiniche
  • Effat Moussa
Originals Articles

DOI: 10.1007/BF02090214

Cite this article as:
Juhl, C.O., Jensen, L.S., Steiniche, T. et al. Digest Dis Sci (1994) 39: 393. doi:10.1007/BF02090214

Abstract

Human epidermal growth factor (EGF), a naturally occurring protein, has been implicated in the protection of gastrointestinal mucosal integrity. The efficacy of EGF in the prevention of sclerotherapy-induced esophageal lesions was investigated in 18 minipigs with surgically induced portal hypertension. The animals underwent five weekly sessions of sclerotherapy with polidocanol 2% and were concomitantly treated with either placebo or EGF administered either paravenously or subcutaneously. EGF significantly (P<0.05) reduced esophageal ulcerations, stricture formations, and mucosal histological damage associated with sclerotherapy. The drug was well-tolerated with no overt toxicity. These results suggest a potentially important clinical value of EGF as an adjunctive treatment with the sclerotherapy.

Key words

esophageal varicesAethoxysclerolportal hypertensionsclerotherapyurogastrone

Copyright information

© Plenum Publishing Corporation 1994

Authors and Affiliations

  • Claus Orloff Juhl
    • 3
    • 1
  • Lone Susanne Jensen
    • 3
    • 1
  • Torben Steiniche
    • 3
    • 1
  • Effat Moussa
    • 3
    • 1
  1. 1.Department of PathologyAarhus County HospitalAarhusDenmark
  2. 2.De Paul UniversityChicago
  3. 3.Institute of Experimental Clinical ResearchUniversity of AarhusAarhus CDenmark